International Foundation of Employee Benefit Plans.
TrustedOverview
Mentions in press and media 23
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Nov 7, 2025 | Millions more Americans could access obesity drugs after Trump’s deals with Eli Lilly, Novo Nordisk | President Donald Trump struck landmark deals with Eli Lilly and Novo Nordisk that could mark a turning point in access to their costly blockbuster obesity drugs. Medicare will start covering GLP-1s for obesity for certain patients for the f... |
| Nov 2, 2025 | Where the blockbuster weight loss drug market stands today — and what’s coming next | The blockbuster weight loss drug market is entering a new chapter of growth. Eli Lilly and Novo Nordisk are both focused on fighting for market share, ramping up supply, testing new uses for their medicines and bringing the next wave of obe... |
| Jul 20, 2025 | Weight loss drugs could be a gamechanger for women with a common hormonal disorder | Several women who have reported improvements in symptoms of polycystic ovary syndrome, a common hormonal disorder, after using GLP-1s such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. Patients and some health experts view GLP-1s as a ... |
| Aug 13, 2024 | MagnaCare's Nick Bonaldo elected to IFEBP Board | SVP to serve two-year term for educational foundation focused on worker benefits NEW YORK, Aug. 13, 2024 /PRNewswire/ -- Nick Bonaldo, Senior Vice President of Sales and Account Management at MagnaCare, has been elected to serve a two-year ... |
| Mar 4, 2024 | Weight-loss drug restrictions shine spotlight on imbalance in obesity care | Tightening restrictions on who can receive the remarkably effective class of new weight-loss drugs is putting a spotlight on an imbalance in how health plans cover obesity care. Why it matters: The explosive growth of Ozempic and other drug... |
| Feb 15, 2024 | Weight-Loss Drugs: Cost and Cost-Effectiveness | Drugs like Wegovy and Zepbound are effective in helping people lose weight, but the high price tag keeps them out of reach for many. Our series on weight-loss drugs continues with a look at the drugs’ cost and whether they are cost-effectiv... |
| Oct 31, 2023 | Yuzu wants to make health plans cheaper by letting insurers mix and match benefits | In the U.S., figuring out ways to pay for health insurance is a perennial problem — not just for individuals, but for the businesses employing them. Companies pay upwards of $22,000 per employee for family coverage, according to health poli... |
| May 17, 2023 | The CEO of virtual-care veteran Omada shares why he's avoiding the race to prescribe trendy new weight-loss drugs and what he's doing instead | Sean Duffy, CEO of the chronic-care provider Omada Health. Omada Health This story is available exclusively to Insider subscribers. Become an Insider and start reading now. Redeem now The rise of buzzy drugs like Ozempic has upended the wei... |
| Apr 13, 2023 | The lives at stake in the battle over Ozempic | Redeem now Like millions of other Americans, Darrell desperately wants to lose weight. The 76-year-old retiree from Aurora, Colorado, has severe obesity along with a number of other conditions, including high cholesterol, sleep apnea, and c... |
Reviews 0
FAQ about International Foundation of Employee Benefit Plans.
When was International Foundation of Employee Benefit Plans. founded?
International Foundation of Employee Benefit Plans. was founded in 1954.
What has the press written about International Foundation of Employee Benefit Plans.?
Parsers VC has collected 23 articles mentioning International Foundation of Employee Benefit Plans., among them “Millions more Americans could access obesity drugs after Trump’s deals with Eli Lilly, Novo Nordisk” (Nov 7, 2025) and “Where the blockbuster weight loss drug market stands today — and what’s coming next” (Nov 2, 2025).
Is International Foundation of Employee Benefit Plans. still active?
Yes, International Foundation of Employee Benefit Plans. is active; its latest activity on Parsers VC dates from Aug 5, 2026.